Neurology. 2009 May 12;72(19):1693-701.

MRI features of benign multiple sclerosis: toward a new definition of this disease phenotype.

Rovaris M, Barkhof F, Calabrese M, De Stefano N, Fazekas F, Miller DH, Montalban X, Polman C, Rocca MA, Thompson AJ, Yousry TA, Filippi M.

Source

Multiple Sclerosis Centre, Scientific Institute Santa Maria Nascente, Fondazione Don Gnocchi, Milan, Italy.

Abstract

It is well known that the current classification of patients with benign multiple sclerosis (BMS), i.e., those with absent or minimal locomotor disability several years after disease onset, suffers from not having any prognostic value for the subsequent evolution of multiple sclerosis (MS). The identification of markers predictive of the longer-term course of MS will help define BMS more reliably and would allow better counseling of patients, particularly when advising on the initiation of a disease-modifying treatment. MRI-based evidence suggests that there are three potential, but not mutually exclusive, explanations for the scarce clinical impact of BMS: 1) the paucity of tissue damage within and outside MS lesions; 2) the relative sparing of clinically eloquent regions; and 3) the presence of effective compensatory mechanisms. In addition, the results of correlative MRI/neuropsychology studies underpin the need for a new definition of BMS, which should consider the maintenance of a normal cognitive profile as an additional criterion.

PMID:: 19433744; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

Biological Markers

LinkOut - more resources

Full Text Sources

Other Literature Sources

COS Scholar Universe

Medical

Supplemental Content

Save items

Related citations in PubMed

Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis. [Neurology. 2009]
Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis.
Portaccio E, Stromillo ML, Goretti B, Zipoli V, Siracusa G, Battaglini M, Giorgio A, Bartolozzi ML, Guidi L, Sorbi S, et al. Neurology. 2009 Aug 18; 73(7):498-503. Epub 2009 Jul 29.
Cognitive impairment and structural brain damage in benign multiple sclerosis. [Neurology. 2008]
Cognitive impairment and structural brain damage in benign multiple sclerosis.
Rovaris M, Riccitelli G, Judica E, Possa F, Caputo D, Ghezzi A, Bertolotto A, Capra R, Falautano M, Mattioli F, et al. Neurology. 2008 Nov 4; 71(19):1521-6. Epub 2008 Sep 24.
Cognitive assessment and quantitative magnetic resonance metrics can help to identify benign multiple sclerosis. [Neurology. 2008]
Cognitive assessment and quantitative magnetic resonance metrics can help to identify benign multiple sclerosis.
Amato MP, Portaccio E, Stromillo ML, Goretti B, Zipoli V, Siracusa G, Battaglini M, Giorgio A, Bartolozzi ML, Guidi L, et al. Neurology. 2008 Aug 26; 71(9):632-8.
Review The definition of non-responder to multiple sclerosis treatment: neuroimaging markers. [Neurol Sci. 2008]
Review The definition of non-responder to multiple sclerosis treatment: neuroimaging markers.
Rovaris M. Neurol Sci. 2008 Sep; 29 Suppl 2:S222-4.
Review The role of MRS and fMRI in multiple sclerosis. [Adv Neurol. 2006]
Review The role of MRS and fMRI in multiple sclerosis.
Tartaglia MC, Arnold DL. Adv Neurol. 2006; 98:185-202.

See reviews... See all...

Cited by 3 PubMed Central articles

When to initiate disease-modifying drugs for relapsing remitting multiple sclerosis in adults? [Mult Scler Int. 2011]
When to initiate disease-modifying drugs for relapsing remitting multiple sclerosis in adults?
Alkhawajah M, Oger J. Mult Scler Int. 2011; 2011:724871. Epub 2011 May 17.
Multiple Sclerosis Severity Scale and whole-brain N-acetylaspartate concentration for patients' assessment. [Mult Scler. 2012]
Multiple Sclerosis Severity Scale and whole-brain N-acetylaspartate concentration for patients' assessment.
Rigotti DJ, Gass A, Achtnichts L, Inglese M, Babb JS, Naegelin Y, Hirsch J, Amann M, Kappos L, Gonen O. Mult Scler. 2012 Jan; 18(1):98-107. Epub 2011 Sep 15.
Global N-acetylaspartate declines even in benign multiple sclerosis. [AJNR Am J Neuroradiol. 2011]
Global N-acetylaspartate declines even in benign multiple sclerosis.
Rigotti DJ, Gonen O, Grossman RI, Babb JS, Falini A, Benedetti B, Filippi M. AJNR Am J Neuroradiol. 2011 Jan; 32(1):204-9. Epub 2010 Oct 21.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

MRI features of benign multiple sclerosis: toward a new definition of this disea...
MRI features of benign multiple sclerosis: toward a new definition of this disease phenotype.
Neurology. 2009 May 12 ;72(19):1693-701.

PubMed
Dietary fatty acids and the 10-year incidence of age-related macular degeneratio...
Dietary fatty acids and the 10-year incidence of age-related macular degeneration: the Blue Mountains Eye Study.
Arch Ophthalmol. 2009 May ;127(5):656-65.

PubMed
Validation of a new retinopathy of prematurity screening method monitoring longi...
Validation of a new retinopathy of prematurity screening method monitoring longitudinal postnatal weight and insulinlike growth factor I.
Arch Ophthalmol. 2009 May ;127(5):622-7.

PubMed
Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?
Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?
J Clin Oncol. 2009 Jul 20 ;27(21):3459-64. Epub 2009 May 11 .

PubMed
Emergent epidural blood patch: lifesaving treatment of paradoxical herniation.
Emergent epidural blood patch: lifesaving treatment of paradoxical herniation.
Arch Neurol. 2009 May ;66(5):670-1.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: